Since its creation, our company, Biopharm, has not stopped to progress in order to assert itself as a leading player in the pharmaceutical sector, and more generally, public health in Algeria. Our success has been made possible by the commitment without flaws of our professional teams and the know-how of each of our collaborators. Clearly, the pharmaceutical quality, which figure in the first rank of our concerns, is inseparably linked to that of human resources, as stipulated in the good manufacturing practices or good distribution practices. That is why; we consider of the utmost importance that each, among women and men which animate our company, can have the appropriate working conditions, of a nature to ensure its promotion and individual fulfillment, as well as of opportunities for training and development ongoing.

Thanks to a commercial network dense and covering up to the more far-flung areas of the country, consisting of 14 distribution centers, over 150 wholesalers and 3000 pharmacies, today we are able to deliver almost 4000 pharmaceutical products on the whole of the Algerian territory. This network is also the support of strong relationships and perennials that we have gradually created with more than 50 international laboratories among the most renowned (Abbott; Alcon; Astra Zeneca; Bayer; Bohringer Ingelheim; Cipla; Merck; Pierre Fabre; etc.). Our distribution network wholesaler, turned toward the satisfaction of our clients, is certified since 2008 according to the repository Quality ISO 9001.

BIOPHARM has also made an ambitious industrial investment consisting of a manufacturing unit of drugs designed following the best international standards. Built at Oued Smar on a site of 8 000 m2, this unit is able to put on the market up to 50 million units every year, through its nine lines of production, for the forms liquid, pasty, and dry. Our concern for the respect of Good practices for pharmaceutical Manufacturing and the attention that we pay to the continuous training of our staff, have been crowned during the year 2015, by the certification of the MSNA to the good manufacturing practices, the French National Agency for the safety of medicines and health products, which empowers the products manufactured on our site to be put on sale on the French and European market.

BIOPHARM will continue over the next few years to support the growth of the national pharmaceutical market by the determined pursuit of its investment efforts, as well as of the extension of its commercial network that the development of its industrial capacity. It expects also to expand the scope of its markets by the consolidation of positions that it has begun to take on African markets and by the entry on the European markets that today are opening to it. BIOPHARM approaches this new phase of its development with its ambitions ‘means.